(Adds sales forecast, more details)
LONDON Aug 13 AstraZeneca, which fended
off a $118 billion takeover approach from Pfizer in May,
reported positive results for an experimental gout drug on
Wednesday that could boost its sales modestly.
The drug, lesinurad, is not forecast by analysts to be a
major seller but its success in three late-stage clinical trials
is a vindication of AstraZeneca's ability to develop new
medicines and comes after recent progress in cancer treatments.
The three Phase III studies all showed the potential of
lesinurad, a selective uric acid re-absorption inhibitor, for
use in combination with existing medicines as a treatment for
gout - a painful joint condition caused by the build-up of uric
acid in the blood.
However, the drug did also cause more side effects,
especially at higher doses, than seen with the older drugs used
on their own.
The company said detailed results would be submitted to a
scientific meeting later this year, and it would prepare a
regulatory submission for a 200 mg dose of the drug in
Industry analysts forecast annual sales of lesinurad to
reach $281 million by 2019, according to consensus forecasts
compiled by Thomson Reuters Pharma.
AstraZeneca acquired lesinurad after buying U.S. company
Ardea Biosciences for $1.26 billion two years ago.
(Reporting by Paul Sandle and Ben Hirschler; editing by James
Davey and Tom Pfeiffer)